SCHEMBL29924523

SCHEMBL29924523

CC(C)(C)OC(=O)N(CCCNC(=O)OCc1ccccc1)CC(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.50
MAPT P10636 1/20 0.48
CA14 Q9ULX7 1/20 0.48
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CCR6 P51684 1/20 0.46
PAX8 Q06710 1/20 0.46
TGM2 P21980 1/20 0.46
KEAP1 Q14145 3/20 0.45
NFE2L2 Q16236 3/20 0.45
TPSAB1 Q15661 2/20 0.44
TPSD1 Q9BZJ3 2/20 0.44
TPSG1 Q9NRR2 2/20 0.44
SYK P43405 1/20 0.44
IDO1 P14902 1/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
FOLH1 Q04609 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22123600 0.88 HTT (0.53) HTTMAPTCA14LMNASMN1; SMN2
SCHEMBL9772169 0.87 MAPT (0.55) HTTMAPTCA14LMNASMN1; SMN2
SCHEMBL29924954 0.87 HTT (0.54) HTTMAPTLMNASMN1; SMN2CCR6
SCHEMBL23728698 0.86 MAPT (0.52) HTTMAPTLMNASMN1; SMN2TGM2
SCHEMBL30135570 0.86 HTT (0.51) HTTMAPTCA14LMNASMN1; SMN2
SCHEMBL4927806 0.86 HTT (0.51) HTTMAPTCA14LMNASMN1; SMN2
SCHEMBL9766146 0.86 CCR6 (0.52) HTTMAPTCA14LMNASMN1; SMN2
SCHEMBL30135568 0.86 HTT (0.51) HTTMAPTCA14LMNASMN1; SMN2
SCHEMBL16596906 0.85 MAPT (0.51) HTTMAPTLMNASMN1; SMN2CCR6
SCHEMBL20467679 0.85 CCR6 (0.51) HTTMAPTCA14LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4274569-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2023-11-15 EP disclosed
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-11-24 US disclosed
WO-2022150316-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2022-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220370431-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 HTT 1984/4885MAPT 3215/4885CA14 4579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.